
LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China
— LIB Therapeutics to receive up to $325 million in upfront and milestone payments in addition to royalties — Hasten obtains rights to develop and […]














